Comparing Investments: Guided Therapeutics and CeriBell

Guided Therapeutics (OTCMKTS:GTHP) and CeriBell (NASDAQ:CBLL) are both small-cap companies focused on the medical sector. Investors might wonder which of these companies presents a better investment opportunity. In this analysis, we will explore various factors, including the strength of dividends, valuation, profitability, institutional ownership, risk profiles, analyst recommendations, and earnings performance of both companies.

Profitability

To evaluate their profitability, we can look at key metrics such as net margins, return on equity, and return on assets, which help gauge how effectively these companies are generating profit.

	Net Margins	Return on Equity	Return on Assets
Guided Therapeutics	N/A	N/A	-151.93%
CeriBell	N/A	N/A	N/A

Valuation & Earnings

Next, let's compare the revenue and earnings metrics of both companies to understand their valuations better.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Guided Therapeutics	$100,000.00	62.72	-$3.49 million	($0.03)	-3.20
CeriBell	$65.44 million	12.79	N/A	N/A	N/A

CeriBell has significantly higher revenue and earnings compared to Guided Therapeutics.

Institutional & Insider Ownership

In terms of ownership, 9.7% of Guided Therapeutics shares are owned by institutional investors. Notably, 66.8% of its shares are held by insiders. This strong insider ownership often indicates confidence in the company’s long-term potential from those closely involved with its operations.

Analyst Recommendations

Analysts have rated these companies, providing insights into investor sentiment.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Guided Therapeutics	0	0	0	0	0.00
CeriBell	0	0	6	0	3.00

CeriBell enjoys a favorable consensus target price of $32.60, suggesting a potential upside of 39.67%. This indication, coupled with a stronger consensus rating, positions CeriBell as a more attractive investment compared to Guided Therapeutics.

Summary

In summary, CeriBell outperforms Guided Therapeutics across five out of eight comparative factors, showcasing its relative strength in the marketplace.

About Guided Therapeutics

Guided Therapeutics, Inc. focuses on developing innovative medical devices. Specifically, it produces LuViva, a non-invasive device for detecting cervical cancer and pre-cancerous conditions by analyzing light reflections from the cervix. Founded in 1992 and based in Norcross, Georgia, the company was previously known as SpectRx, Inc. before rebranding in 2008.

About CeriBell

CeriBell, Inc. is a company committed to improving the diagnosis and management of serious neurological conditions. Its Ceribell System is a cutting-edge, point-of-care electroencephalography (EEG) platform designed for acute care settings. By incorporating advanced AI algorithms and portable hardware, the system allows for rapid diagnosis and monitoring of neurological conditions. As of September 30, 2024, CeriBell has established over 500 active accounts, aiding in the care of more than 100,000 patients. CeriBell is focused on expanding its technology's use and aims to become the standard of care in seizure detection in acute care settings. The company was incorporated in 2014 and is headquartered in Sunnyvale, California.

Receive Updates on Market Trends - Interested readers can enter their email for the latest news and updates regarding Guided Therapeutics and CeriBell.

Investment, Healthcare, Comparison